Boehringer Ingelheim, Lilly get FDA green light for TrijardyThe FDA has approved Trijardy, the only triple-combination tablet with Jardiance for adults with Type 2 diabetes. Epizyme gets FDA nod for TazverikTazverik offers the first treatment option for patients with a rare soft tissue cancer. FDA approves new formulation, indication for Merck’s Dificid Merck has received the FDA's blessing for a pediatric indication for Dificid, as well as an oral suspension formulation. Merck to acquire ArQule Merck’s acquisition of ArQule diversifies its oncology pipeline. Ironwood, Allergan settle patent suit with Teva The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg Linzess is March 2029. FDA clears Horizon Therapeutics’ Tepezza Tepezza is the first approved treatment for thyroid eye disease. Hikma, Arecor to develop ready-to-use injectable medicine Hikma and Arecor's new product uses Arecor’s drug formulation technology platform Arestat. Lilly to offer two more lower-priced versions of insulin products The list price for Lill's Humalog Mix75/25 KwikPen and Humalog Junior KwikPen will be 50% less than branded versions. FDA approves diazepam nasal spray Valtoco Valtoco is the first nasal spray approved by the Food and Drug Administration as a rescue treatment for people with epilepsy age 6 years old and older. Lannett gets FDA nod for Numbrino Lannett expects to launch Numbrino nasal solution shortly. First Previous 30 31 32 33 34 Next Last